Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape.

Martin CJ, Datta A, Littlefield C, Kalra A, Chapron C, Wawersik S, Dagbay KB, Brueckner CT, Nikiforov A, Danehy FT Jr, Streich FC Jr, Boston C, Simpson A, Jackson JW, Lin S, Danek N, Faucette RR, Raman P, Capili AD, Buckler A, Carven GJ, Schürpf T.

Sci Transl Med. 2020 Mar 25;12(536). pii: eaay8456. doi: 10.1126/scitranslmed.aay8456.

PMID:
32213632
2.

Structural basis for specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015.

Dagbay KB, Treece E, Streich FC Jr, Jackson JW, Faucette RR, Nikiforov A, Lin SC, Boston CJ, Nicholls SB, Capili AD, Carven GJ.

J Biol Chem. 2020 Feb 19. pii: jbc.RA119.012293. doi: 10.1074/jbc.RA119.012293. [Epub ahead of print]

3.

Assessing the Impact of Charge Variants on Stability and Viscosity of a High Concentration Antibody Formulation.

Sule SV, Fernandez JE, Mecozzi VJ, Kravets Y, Yang WC, Feng P, Liu S, Zang L, Capili AD, Estey TB, Gupta K.

J Pharm Sci. 2017 Dec;106(12):3507-3514. doi: 10.1016/j.xphs.2017.08.016. Epub 2017 Aug 30.

PMID:
28860086
4.

Determining the affinity and stoichiometry of interactions between unmodified proteins in solution using Biacore.

Day ES, Capili AD, Borysenko CW, Zafari M, Whitty A.

Anal Biochem. 2013 Sep 1;440(1):96-107. doi: 10.1016/j.ab.2013.05.012. Epub 2013 May 24.

PMID:
23711722
5.

Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties.

Vendel MC, Favis M, Snyder WB, Huang F, Capili AD, Dong J, Glaser SM, Miller BR, Demarest SJ.

Arch Biochem Biophys. 2012 Oct 15;526(2):188-93. doi: 10.1016/j.abb.2011.12.018. Epub 2012 Jan 2.

PMID:
22230329
6.

Active site remodelling accompanies thioester bond formation in the SUMO E1.

Olsen SK, Capili AD, Lu X, Tan DS, Lima CD.

Nature. 2010 Feb 18;463(7283):906-12. doi: 10.1038/nature08765.

7.

Designed semisynthetic protein inhibitors of Ub/Ubl E1 activating enzymes.

Lu X, Olsen SK, Capili AD, Cisar JS, Lima CD, Tan DS.

J Am Chem Soc. 2010 Feb 17;132(6):1748-9. doi: 10.1021/ja9088549.

8.

A molecular basis for phosphorylation-dependent SUMO conjugation by the E2 UBC9.

Mohideen F, Capili AD, Bilimoria PM, Yamada T, Bonni A, Lima CD.

Nat Struct Mol Biol. 2009 Sep;16(9):945-52. doi: 10.1038/nsmb.1648. Epub 2009 Aug 16.

9.
10.

The structurally disordered KRAB repression domain is incorporated into a protease resistant core upon binding to KAP-1-RBCC domain.

Peng H, Gibson LC, Capili AD, Borden KL, Osborne MJ, Harper SL, Speicher DW, Zhao K, Marmorstein R, Rock TA, Rauscher FJ 3rd.

J Mol Biol. 2007 Jul 6;370(2):269-89. Epub 2007 Mar 24.

PMID:
17512541
11.
12.
14.

Supplemental Content

Loading ...
Support Center